No I don’t believe so, just a very tired one.
the clinical validation is there. It is also evident that the tests are being used, billed but not paid for. I personally find this a bit of a sham, considering they are using the test and not paying for it - then when the LCM is approved will negotiate a lower bulk payment for sure.
The amount of tests they currently do per year is worth more than the market cap at the agreed price.
the horse is not dead - just tired!
- Forums
- NZX - By Stock
- PEB
- Ann: Completion of Placement
PEB
pacific edge limited
Add to My Watchlist
0.00%
!
9.6¢

Ann: Completion of Placement, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.